Latest news with #Elanco
Associated Press
5 days ago
- Business
- Associated Press
Elanco CEO Jeff Simmons: Innovation and Sustainability Drive Long-Term Growth
Jeff Simmons, President and CEO of Elanco Animal Health, recently joined the Bloomberg Businessweek Daily to discuss the company's strategic framework and detail why he sees sustainable value creation continuing for years to come. 'I see this as one of the most resilient industries right now with some of the consumer trends that are out there,' Simmons shared. Simmons went on to emphasize the value of innovation as a driver of the growth at the company, including how its work in the cattle space is meeting the changing expectations of consumers. 'We've got a couple products here that are actually helping with productivity and low cattle numbers that are out there. That's why beef prices are a little higher, but also having an environmental impact. And CPG companies are signing up to say, hey, this is important to the next generation of protein consumers,' Simmons explained. This discussion comes on the heels of the company's recently-released 2024 Impact Report, which showcases Elanco's efforts to enhance animal care, not just improving the lives of animals but also the people who care for them. Listen to the full interview here. Learn more about Elanco's commitments to animal health and how making life better for animals makes life better. Visit 3BL Media to see more multimedia and stories from Elanco
NZ Herald
7 days ago
- Health
- NZ Herald
Elanco supports Meet the Need
Elanco is supporting Meet the Need with every pack of Prolaject sold between July 1 and September 30, 2025. Doing good in your community could be great for your clinic, too. This winter, rural vet clinics across New Zealand have the chance to do something truly meaningful - supporting animal health while feeding families in need. In partnership with Meet the Need, the farmer-founded food charity, Elanco is connecting
Yahoo
08-08-2025
- Business
- Yahoo
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost
We recently published . Elanco Animal Health Inc. (NYSE:ELAN) is one of the best-performing stocks on Thursday. Elanco saw its share prices surge to a new 52-week high on Thursday as investors cheered its strong earnings performance in the second quarter of the year. During the session, Elanco Animal Health Inc. (NYSE:ELAN) jumped by as high as 19.7 percent to its highest price of $16.7 before ending the day just up by 18.14 percent at $16.48 apiece. This followed the release of its earnings performance that saw the company swing to a net income of $11 million from a $50 million net loss in the same period last year. Revenues grew by 4.8 percent to $1.24 billion from $1.18 billion in the same comparable period. In the first half, Elanco Animal Health Inc. (NYSE:ELAN) incurred a net income of $78 million, reversing an $18 million net loss in the same period last year. Revenues also inched up by 2 percent to $2.434 billion from $2.389 billion year-on-year. For the full-year period, Elanco Animal Health Inc. (NYSE:ELAN) expects to incur a higher net loss of $14 million to $38 million versus the $7 million to $35 million previously. Pixabay/Public Domain Revenue target, however, was increased to $4.57 billion to $4.62 billion, from $4.51 billion to $4.58 billion previously. While we acknowledge the potential of ELAN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Business
- Yahoo
Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook
Elanco Animal Health Incorporated (NYSE:ELAN) reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year. Despite the decline, earnings exceeded both the company's guidance range of 17 cents to 21 cents and the consensus estimate of 20 cents. Revenue came in at $1.24 billion, surpassing the consensus estimate of $1.19 billion and exceeding management's guidance of $1.175 billion to $1.195 billion. Sales grew 5% on a reported basis and 8% on an organic constant currency EBITDA was $238 million in the second quarter of 2025, a 13.5% decrease. Pet Health revenue was $643 million, an increase of 11% on a reported basis, or 10% on an organic constant currency basis. The increase in pet health revenue included a 4% increase in price. New products primarily drove year-over-year volume increases of 6%. The Advantage Family of products and Seresto contributed revenue of $147 million and $113 million, respectively. Farm Animal revenue was $583 million, a decrease of 2% on a reported basis due to the sale of the aqua business, and a 6% increase on an organic constant currency basis. Farm animal organic constant currency revenue growth included a 2% increase from price. Volumes were up 4%, driven by increased volumes in U.S. cattle, led by Experior, and increased volumes in international poultry and swine. The business has seen demand recovery for international swine products, while international poultry demand remains strong. View more earnings on ELAN Sales of the company's international farm animal products benefited from accelerated customer purchases, primarily in China, in advance of expected future tariff increases, estimated to have shifted approximately $10 to $20 million of expected future purchases to the second quarter. Commenting on Elanco's earnings, William Blair said, 'Elanco's second-quarter deck has some positive key product updates for Zenrelia (label update in the U.S.), Quattro (increased sell-through in the second quarter), AdTab (60% growth), and Experior/Bovaer (continued momentum).' Analyst Brandon Vazquez of William Blair said the solid second-quarter update reinforced the belief that Elanco is on track for a multi-year period of improving growth and margins. Full-Year Guidance 'We are raising our 2025 full-year guidance for our strong second quarter execution and more favorable foreign exchange rates, more than offsetting incremental investments to fuel our innovation launches...,' said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. Elanco anticipates a tailwind to revenue of approximately $35 million from the favorable impact of foreign exchange rates compared with the May earnings call. The company raised fiscal 2025 revenue guidance from $4.51 billion-$4.58 billion to $4.57 billion-$4.62 billion versus the consensus of $4.54 billion. Elanco also increased its 2025 adjusted EPS from 80-86 cents to 85-91 cents versus the consensus of 84 cents. Full year adjusted EBITDA includes a current estimate for net tariff impact of $10 to $14 million versus $16 to $20 million previously. Third-Quarter Guidance Elanco expects a tailwind to revenue of approximately $10 million from the favorable impact of foreign exchange rates compared to the prior year. Excluding the impacts of foreign exchange rates and royalty revenue sold to a third party, the company expects a growth of 4%-6% in organic constant currency revenue. Elanco forecasts third-quarter adjusted earnings of 12-16 cents per share versus the consensus of 13 cents, with sales of $1.08 billion-$1.11 billion compared to the Wall Street estimate of $1.083 billion. The company anticipates growth to be impacted by approximately $15 million in revenue and approximately $10 million in Adjusted EBITDA of pre-tariff customer buying accelerated into the second quarter, primarily in China. Price Action: ELAN stock surged to a 52-week high of $15.79 following the release of stronger-than-expected financial results for the second quarter of 2025. The stock is trading higher by 17.1% to $16.34 at last check Wednesday. Read Next:Photo by T Sxhneider via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
25-07-2025
- Business
- Yahoo
Why Elanco (ELAN) Stock Is Trading Up Today
What Happened? Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia. The treatment, Zenrelia, was approved as a once-daily oral medication to treat itching and atopic dermatitis in dogs. This decision by the European Commission represented a significant milestone for Elanco, allowing it to expand its presence in the European canine dermatology market. The company stated the product was expected to be available by the end of the third quarter of 2025. The news followed a recent analyst upgrade from UBS Group, which raised its price target on Elanco shares to $18.00 from $17.00, reiterating a 'buy' rating on the stock. After the initial pop the shares cooled down to $14.85, up 1.1% from previous close. Is now the time to buy Elanco? Access our full analysis report here, it's free. What Is The Market Telling Us Elanco's shares are quite volatile and have had 16 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 21.2% on the news that the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included constant currency revenue outperformance. Organic sales were up 4%, thanks to strong demand in cattle health and good traction from new pet meds like Credelio Quattro. Even though sales were flat, operating margins improved, a sign they're managing prices and costs pretty well. On the other hand, its full-year EBITDA guidance missed. Overall, we think this was a decent quarter with some key metrics above expectations. Elanco is up 23.2% since the beginning of the year, and at $14.85 per share, it is trading close to its 52-week high of $15.47 from August 2024. Investors who bought $1,000 worth of Elanco's shares 5 years ago would now be looking at an investment worth $696.95. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
